ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AMGN Amgen Inc

311.29
0.00 (0.00%)
Pre Market
Last Updated: 10:09:40
Delayed by 15 minutes
Share Name Share Symbol Market Type
Amgen Inc NASDAQ:AMGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 311.29 311.25 312.75 214 10:09:40

Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference

04/01/2017 9:00pm

PR Newswire (US)


Amgen (NASDAQ:AMGN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Amgen Charts.

THOUSAND OAKS, Calif., Jan. 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 35th Annual J.P. Morgan Healthcare Conference at 2 p.m. PT on Monday, Jan. 9, 2017, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300385773.html

SOURCE Amgen

Copyright 2017 PR Newswire

1 Year Amgen Chart

1 Year Amgen Chart

1 Month Amgen Chart

1 Month Amgen Chart

Your Recent History

Delayed Upgrade Clock